Avalo Therapeutics

Seasoned biopharmaceutical executive and entrepreneur with over 30 years of industry experience. Founder of Collegium Pharmaceutical and has built and led multiple companies through financings and successful exits. Held leadership positions at Onset Dermatologics, Clinical Studies Ltd., and Eli Lilly.

CFO since February 2022 with strong public company and life sciences finance background. Previously served as Corporate Controller at Sucampo Pharmaceuticals (during its $1.2 billion merger with Mallinckrodt) and OpGen. Experienced in capital raises, M&A transactions, and enterprise resource planning in biotech and pharmaceutical sectors.

Over 20 years of biotech and pharma leadership experience. Previously founder and Principal of Northbrook Consulting providing operational support to biopharmaceutical companies. Held senior roles at Biogen including VP of Program Leadership overseeing hemophilia franchise strategy and VP Global Cardiopulmonary Marketing.

Research physician with over 20 years of pharma and biotech experience and numerous clinical development leadership roles. Most recently Chief Medical Officer at Aro Biotherapeutics; previously held senior immunology and therapeutic area head positions at CSL Behring, Shire, Flexion, and Alexion, advancing assets across immune-mediated and orphan disease indications.

Legal counsel with 25 years of pharma and biotech industry experience. Most recently US General Counsel at Idorsia Pharmaceuticals US. Previously held General Counsel roles at Amarin and Braeburn, and spent 12 years at GSK in progressively senior legal positions. Also has FDA regulatory counsel experience.

Nearly 15 years of biotech business development, corporate finance, and investment banking experience. Recently served as Executive Vice President and Chief Business Officer at Abzena leading M&A and licensing initiatives. Previously VP and Head of Business Development at Longboard Pharmaceuticals (acquired for $2.6 billion by Lundbeck) and held investment banking roles executing over $40 billion in transactions.

Seasoned HR executive with nearly 20 years driving organizational growth in biotech and pharmaceutical sectors. Previously Head of Human Resources at Venatorx Pharmaceuticals where she built the HR function during expansion. Held leadership roles at Aralez, Endo International, and Auxilium, and served as Principal HR Consultant advising life sciences companies.

Over 25 years of biopharmaceutical regulatory experience. Previously Senior Global Regulatory Consultant focusing on rare disease therapies. Held Head of Regulatory Affairs role at Aclaris leading global programs, and held regulatory positions at Takeda, BioMarin, ViroPharma, Endo, Cephalon, and Wyeth. Began career at the FDA's Office of Regulatory Affairs.

Over 25 years of pharmaceutical development experience in analytical chemistry and product development. Previously Executive Director at Alexion leading analytical and pharmaceutical development groups supporting development and commercialization of multiple rare disease therapies including Soliris, Strensiq, Kanuma, and Ultomiris.

Over 25 years of clinical research and development experience. Previously held leadership roles in small biotech overseeing clinical development and program management across cross-functional teams. Spent over two decades at a leading global CRO in various project management and operational positions, including leading the program for the first FDA-approved angiogenesis-targeting therapy.

Founder and Managing Partner of Scion Life Sciences with over a decade specializing in founding and investing in biotech companies. Founding board member of Tourmaline Bio, Centessa Pharmaceuticals, and RayzeBio (acquired by Bristol Myers Squibb). Previously Partner at Apple Tree Partners as a venture capital investor and board member of multiple companies including Akero Therapeutics, Corvidia, and Syntimmune.

Recognized authority on host immune response to mycobacterial pathogens including agents causing leprosy and tuberculosis. Previously Director of Global Health Tuberculosis program at Bill & Melinda Gates Foundation (2014–2018). Spent 20 years at Rockefeller University and 10 years at Public Health Research Institute Center leading immunology research and receiving multiple NIH-NIAID grants.

Seasoned biotechnology executive with over 20 years of leadership experience. Most recently President, CEO, and Board Member of Longboard Pharmaceuticals, leading its transformation and $2.6 billion acquisition by H. Lundbeck A/S in 2024. Previously Executive Vice President and CFO at Arena Pharmaceuticals. Career includes investment banking at Lehman Brothers and healthcare investing at TPG, with over a billion dollars in capital raised.

Rheumatologist with over two decades of biopharmaceutical leadership in clinical strategy and regulatory affairs across immunology, inflammation, nephrology, and rare diseases. Most recently Executive Vice President and Chief Medical Officer at ChemoCentryx where she advanced development of Tavneos (avacopan) prior to Amgen acquisition. Previously SVP and CMO at Akebia and held key positions at AbbVie, Pfizer, and Immunovant.

Executive Chair of CREATE Medicines pioneering targeted multi-immune therapies. Previously President and CEO of Orbital Therapeutics (acquired by Bristol Myers Squibb). Held successive leadership roles at Spark Therapeutics culminating in CEO, leading launch of LUXTURNA® (first FDA-approved gene therapy for genetic disease) and positioning the company for acquisition by Roche. Earlier experience includes decade at Pfizer and Wyeth in senior global leadership roles.

CEO of Oblenio Bio and CEO-in-Residence at Aditum Bio. Previously founding CEO of Upstream Bio, CEO of Quench Bio, COO of Synlogic, and CBO for Padlock Therapeutics. Held VP of Corporate Development role at Biogen leading transactions and serving as program executive for marketed products. Also has corporate development experience at Genzyme and Chiron Diagnostics.